dual agonist glp-1 glucagon GLP-1R and Diabetes Glucagon-Like Peptide-1 Based Therapies: A

The key question for investors is whether these new categories can meaningfully offset the pressure in weight management and whether HIMS can build durable, compliant businesses in these segments

For example, in clinical trials of semaglutide (Ozempic) for type 2 diabetes, headaches were reported in approximately 4-8% of patients depending on dose

Ann Pharmacother 2009

maintain*

As a result, some healthcare providers may prescribe Ozempic for weight loss in individuals who do not have diabetes, especially for those struggling with obesity or overweight-related health issues

By addressing root causes while using semaglutide or tirzepatide, you can achieve lasting results rather than temporary weight loss